JP4721640B2 - フェノフィブラートのナノ粒子製剤 - Google Patents

フェノフィブラートのナノ粒子製剤 Download PDF

Info

Publication number
JP4721640B2
JP4721640B2 JP2003518484A JP2003518484A JP4721640B2 JP 4721640 B2 JP4721640 B2 JP 4721640B2 JP 2003518484 A JP2003518484 A JP 2003518484A JP 2003518484 A JP2003518484 A JP 2003518484A JP 4721640 B2 JP4721640 B2 JP 4721640B2
Authority
JP
Japan
Prior art keywords
fenofibrate
measured
nanosuspension
vitamin
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003518484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509596A6 (ja
JP2005509596A (ja
JP2005509596A5 (https=
Inventor
パスカル グルニエ
ガイ ベルナート
アラン ハミアス
Original Assignee
ヤゴテック アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤゴテック アーゲー filed Critical ヤゴテック アーゲー
Publication of JP2005509596A publication Critical patent/JP2005509596A/ja
Publication of JP2005509596A6 publication Critical patent/JP2005509596A6/ja
Publication of JP2005509596A5 publication Critical patent/JP2005509596A5/ja
Application granted granted Critical
Publication of JP4721640B2 publication Critical patent/JP4721640B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2003518484A 2001-08-09 2002-08-09 フェノフィブラートのナノ粒子製剤 Expired - Fee Related JP4721640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119480.2 2001-08-09
GBGB0119480.2A GB0119480D0 (en) 2001-08-09 2001-08-09 Novel compositions
PCT/GB2002/003687 WO2003013474A1 (en) 2001-08-09 2002-08-09 Nanoparticulate formulations of fenofibrate

Publications (4)

Publication Number Publication Date
JP2005509596A JP2005509596A (ja) 2005-04-14
JP2005509596A6 JP2005509596A6 (ja) 2005-08-04
JP2005509596A5 JP2005509596A5 (https=) 2006-01-05
JP4721640B2 true JP4721640B2 (ja) 2011-07-13

Family

ID=9920132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518484A Expired - Fee Related JP4721640B2 (ja) 2001-08-09 2002-08-09 フェノフィブラートのナノ粒子製剤

Country Status (8)

Country Link
US (1) US8663693B2 (https=)
EP (1) EP1414410B1 (https=)
JP (1) JP4721640B2 (https=)
AT (1) ATE422155T1 (https=)
DE (1) DE60231082D1 (https=)
ES (1) ES2321912T3 (https=)
GB (1) GB0119480D0 (https=)
WO (1) WO2003013474A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
CN1829499A (zh) * 2003-05-29 2006-09-06 格利康科技集团有限责任公司 稳定并控制传递(－)－羟基柠檬酸的方法和组合物
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
US8888736B2 (en) 2010-04-30 2014-11-18 H R D Corporation High shear application in medical therapy
WO2011139479A2 (en) 2010-04-30 2011-11-10 H R D Corporation High shear application in drug delivery
CA2844073C (en) 2010-08-23 2015-10-13 NanoRx, Inc. Policosanol nanoparticles
GB201118181D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Pharmaceutical compositions
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
CN104903494B (zh) * 2012-09-21 2017-11-03 瑞奥可塞恩探索集团有限公司 用于电解液体的电池
US11285115B2 (en) 2013-02-28 2022-03-29 Ramot At Tel-Aviv University Ltd. Peptide-based hydrogel particles and uses thereof
CN105218370A (zh) * 2014-06-10 2016-01-06 无锡康福特药物科技有限公司 一种贝特类降脂药物的超微粉体及其制备方法
PL3833335T3 (pl) * 2019-07-31 2023-01-02 Intas Pharmaceuticals Ltd. Kompozycja farmaceutyczna zawierająca inhibitory reduktazy HMG-CoA i fenofibrat
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
US20230398234A1 (en) * 2020-10-28 2023-12-14 Mydecine Innovations Group Inc. Novel fungal compoind formulations and their therapeutic methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
DE19800250A1 (de) 1997-01-13 1998-08-06 Winter Cvd Technik Gmbh Schleifkörper
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
FR2783421B1 (fr) 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
EP1133280A1 (en) 1998-11-20 2001-09-19 RTP Pharma Inc. Method of preparing stable suspensions of insoluble microparticles
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6464511B1 (en) 1999-11-17 2002-10-15 Advantest Corporation IC socket and IC tester
FR2803203B1 (fr) 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate

Also Published As

Publication number Publication date
GB0119480D0 (en) 2001-10-03
JP2005509596A (ja) 2005-04-14
EP1414410A1 (en) 2004-05-06
ATE422155T1 (de) 2009-02-15
ES2321912T3 (es) 2009-06-15
WO2003013474A1 (en) 2003-02-20
US20050095297A1 (en) 2005-05-05
US8663693B2 (en) 2014-03-04
DE60231082D1 (de) 2009-03-19
EP1414410B1 (en) 2009-02-04

Similar Documents

Publication Publication Date Title
JP4721640B2 (ja) フェノフィブラートのナノ粒子製剤
JP2005509596A6 (ja) フェノフィブラートのナノ粒子製剤
Choi et al. Effects of different physicochemical characteristics and supersaturation principle of solidified SNEDDS and surface-modified microspheres on the bioavailability of carvedilol
Danish et al. Various techniques of bioavailability enhancement: a review
US6368620B2 (en) Formulations comprising lipid-regulating agents
CA2746887C (en) Methods for enhancing the release and absorption of water insoluble active agents
CN101862306B (zh) 新型难溶性药物口服固体自乳化制剂及其制备方法
Parul et al. BIOAVAILABILITY ENHANCDEMENT OF POORLY SOLUBLE DRUGS BY SMEDDS: A
JP2010241820A (ja) 保護被膜を有する再分散性超微粒状フィルムマトリックス
AU4237397A (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO2002024193A1 (en) Stabilised fibrate microparticles
FR2803203A1 (fr) Nouvelles formulations galeniques du fenofibrate
US7255877B2 (en) Fenofibrate microparticles
Meola et al. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro
Goyal et al. Self microemulsifying drug delivery system: A method for enhancement of bioavailability
US20070082054A1 (en) Particle size reduction of bioactive compounds
Bhupinder et al. Self emulsified drug delivery system for the enhancement of oral bioavailability of poorly water soluble drugs
CN100536921C (zh) 过饱和阳离子自乳化给药系统及其制备方法
Poovi et al. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the effect of physicochemical formulation factors in the optimization process, different preparation technique, characterization, and toxicity
Kazi Lipid-Based Nano-Delivery for Oral Administration of Poorly Water Soluble Drugs (PWSDs): Design
CN110623926B (zh) 一种人参三醇过饱和自微乳及其制备方法
Kadam et al. A short review on the important aspects involved in preparation, characterization and application of nanostructured lipid carriers for drug delivery
Bakhatwar et al. Fenofibrate nanosuspension: a novel strategy to enhance its bioavailability for the management of hyperlipidemia
Nandal et al. Novel Approaches of Self Emulsifying Drug Delivery Systems and Recent Patents: A Comprehensive Review
Sri et al. A review on SEDDS and Solid SEDDS: an emerging dosage forms for poorly soluble drugs

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050801

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100610

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110309

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees